



HOSTED LIVE ON:
September 19 & 26, 2025
10:00 am - 4:30 pm EDT

CONFERENCE OBJECTIVES:

- Apply evidence-based and guideline-centric care for patients in primary care
- Determine and understand patient needs to provide patient-centered care

SEPTEMBER 19, 2025

Time	Session Title	Faculty
10:00 am EDT	Welcome & Introduction	
10:05 am EDT	Hot Topics in CKD in T2D: Practical Guidance for Comprehensive Clinical Care	Dr. Akshay Jain
11:15 am EDT	Unlocking Confidence with Once-Weekly Insulin	Dr. Irena Druce
12:15 pm EDT	Virtual Exhibit Hall & Refreshment Break	
1:00 pm EDT	Cracking the Code: Egg Adaptation and Beyond in Influenza Vaccines	Dr. Vivien Brown
2:10 pm EDT	Awareness to Action: HPV Testing, Vaccination, & Cancer Prevention in Clinical Practice	Dr. Cheryl Cable & Dr. Nancy Durand
3:20 pm EDT	GLP-1 RAs: Guardians of Heart and Kidney Health in Type 2 Diabetes	Dr. Upender Mehan
4:30 pm EDT	Closing Remarks	

SEPTEMBER 26, 2025

Time	Session Title	Faculty
10:00 am EDT	Welcome & Introduction	
10:05 am EDT	Recent Advances in the Management of VMS	Dr. Vivien Brown
11:15 am EDT	Differentiating Between the CCS and PEER Lipid Guidelines	Dr. Milan Gupta & Dr. John Mancini
12:15 pm EDT	Virtual Exhibit Hall & Refreshment Break	
1:00 pm EDT	MASLD/MASH in the Era of Metabolic Risk: Practical Updates for Primary Care	Dr. Supriya Joshi
2:10 pm EDT	Beyond the Basics: Enhancing Hepatitis B Diagnosis, Treatment, and Referral in Your Practice	Dr. Scott Fung
3:20 pm EDT	Evolving Obesity Care: Adapting to a New Era	Dr. Sarah Chapelsky
4:30 pm EDT	Closing Remarks	

This received unrestricted educational grants and in-kind support from:
 Amgen, Astellas, Bayer, GSK, Merck, Novo Nordisk and Seqirus



FRIDAY, SEPTEMBER 19, 2025 - DAY 1

10:05 am - 11:05 am

Hot Topics in CKD in T2D: Practical Guidance for Comprehensive Clinical Care

Dr. Akshay Jain

At the conclusion of this activity participants will be able to:

- Identify patients with or at risk of CKD in T2D using updated screening recommendations
- Apply a guideline-recommended approach to treatment initiation, titration, and monitoring in patients with T2D and CKD
- Address common patient questions about risk, treatment options, benefits, and polypharmacy

11:15 am – 12:15 pm

Unlocking Confidence with Once-Weekly Insulin

Dr. Irena Druce

At the conclusion of this activity participants will be able to:

- Provide effective patient education and support strategies to guide initiation and transition to weekly basal insulin therapy.
- Apply evidence-based approaches to calculate appropriate starting doses and adjust titration for weekly basal insulin while minimizing the risk of hypoglycemia.
- Compare the pharmacologic properties, dosing strategies, and titration protocols of weekly versus daily basal insulin.
- Describe the clinical role, risks, and benefits of weekly basal insulin in managing type 2 diabetes across different patient populations.

12:15 pm - 1:00 pm

Virtual Exhibit Hall & Refreshment Break

1:00 pm – 2:00 pm

Cracking the Code: Egg Adaptation and Beyond in Influenza Vaccines

Dr. Vivien Brown

At the conclusion of this activity participants will be able to:

- Describe the key differences between egg-based and cell-based influenza vaccine technologies.
- Evaluate the clinical guidance for influenza vaccination in pediatric populations, especially in children under 5 years of age.
- Analyze how early-life influenza exposure creates immunological imprinting that influences lifetime immune responses to subsequent infections and vaccinations.
- Develop tailored communication strategies to promote influenza immunization and address common parental concerns regarding the vaccine.

2:10 pm – 3:10 pm

Awareness to Action: HPV Testing, Vaccination, & Cancer Prevention in Clinical Practice

Dr. Cheryl Cable &
Dr. Nancy Durand

At the conclusion of this activity participants will be able to:

- Describe the burden of head and neck cancers and the impact of HPV vaccination on the prevention of HPV-related cancers.
- Apply current guidelines for HPV testing and identify barriers to HPV vaccine uptake in clinical practice.
- Develop strategies to effectively overcome common barriers to HPV vaccination.
- Demonstrate increased confidence in recommending HPV vaccination to eligible patients.

3:20 pm – 4:20 pm

GLP-1 RAs: Guardians of Heart and Kidney Health in Type 2 Diabetes

Dr. Upender Mehan

At the conclusion of this activity participants will be able to:

- Implement a holistic approach to cardiovascular risk reduction in people with Type 2 diabetes
- Interpret and apply the 2024 Diabetes Canada guidelines for cardiorenal protection
- Select appropriate pharmacotherapy for people with Type 2 diabetes based on cardiovascular and renal risk profiles
- Develop personalized management plans for people with Type 2 diabetes and chronic kidney disease
- Apply shared decision-making principles when optimizing therapy for cardiorenal protection

FRIDAY, SEPTEMBER 26, 2025 - DAY 2

10:05 am - 11:05 am Recent Advances in the Management of VMS

Dr. Vivien Brown

At the conclusion of this activity participants will be able to:

- Explain the prevalence and burden of vasomotor symptoms (VMS) in perimenopausal and menopausal women
- Apply the clinical guidelines and the latest advances in research for hormonal and nonhormonal treatment options for VMS
- Discuss the benefits, risks, and contraindications of different treatment options for VMS for appropriate treatment selection

11:15 am – 12:15 pm Differentiating Between the CCS and PEER Lipid Guidelines

Dr. Milan Gupta &
Dr. John Mancini

At the conclusion of this activity participants will be able to:

- Explain the history of lipid guidelines development and principles
- Determine what evidence should inform guideline recommendations
- Identify similarities and differences between guidelines in primary and secondary prevention

12:15 pm - 1:00 pm Virtual Exhibit Hall & Refreshment Break

1:00 pm – 2:00 pm

MASLD/MASH in the Era of Metabolic Risk: Practical Updates for Primary Care

Dr. Supriya Joshi

At the conclusion of this activity participants will be able to:

- Identify appropriate screening criteria and diagnostic pathways for MASLD/MASH in primary care settings
- Interpret non-invasive fibrosis assessment tools to stratify patients according to disease severity and progression risk
- Implement evidence-based lifestyle interventions and monitoring strategies for patients with MASLD/MASH
- Evaluate when specialist referral is indicated based on current clinical guidelines and patient-specific factors

2:10 pm – 3:10 pm

Beyond the Basics: Enhancing Hepatitis B Diagnosis, Treatment, and Referral in Your Practice

Dr. Scott Fung

At the conclusion of this activity participants will be able to:

- Critically assess patients at risk for hepatitis B infection and develop a strategy for screening and vaccination
- Diagnose hepatitis B infection through timely, appropriate investigations
- Differentiate between patients who require monitoring only or antiviral treatment for chronic hepatitis B infection
- Assess patient need for specialty care and formulate an effective referral plan

3:20 pm – 4:20 pm

Evolving Obesity Care: Adapting to a New Era

Dr. Sarah Chapelsky

At the conclusion of this activity participants will be able to:

- Develop a primary-care management strategy for obesity as a chronic disease in alignment with current Canadian clinical practice guidelines.
- Apply evidence-based treatment approaches for obesity with a focus on improving obesity-related comorbidities and quality of life.
- Define obesity as a chronic, progressive disease caused by multiple internal and external factors, only some of which are under the individual's control.